Glucose 5% Labesfal

Glucose 5% Labesfal is an intravenous solution that contains glucose at a concentration of 5 % w/v. Marketed under the Labesfal brand, this sterile fluid is classified as an excipient and is used in parenteral nutrition and fluid‑replacement therapy. It is supplied in a ready‑to‑use container for intravenous administration and is prescribed by healthcare professionals in the European Union and complies with EU pharmacopeial standards and guidelines.

Glucose 5% Labesfal is indicated for several clinical situations where intravenous carbohydrate and fluid support are required.

- Fluid and electrolyte replacement in patients unable to tolerate oral intake. - Component of parenteral nutrition regimens to provide an energy source. - Treatment of hypoglycemia when rapid glucose administration is needed. - Peri‑operative fluid management to maintain blood glucose levels. - Support in pediatric and critical‑care settings where caloric intake must be controlled. - Dilution medium for compatible intravenous medications.

Intravenous administration of Glucose 5% Labesfal may be associated with a range of adverse reactions, most of which are related to its glucose content and osmolarity.

Common: - Transient increase in blood glucose levels that may require monitoring. - Local irritation or phlebitis at the infusion site causing redness or pain. - Mild nausea, vomiting, or abdominal discomfort. - Electrolyte shifts, especially a temporary decrease in serum potassium. - Mild fluid overload in patients with borderline cardiac function.

Serious: - Severe hyperglycemia that can precipitate diabetic ketoacidosis. - Anaphylactic or severe allergic reaction with rash, bronchospasm, or hypotension. - Volume overload resulting in pulmonary edema or heart failure exacerbation. - Metabolic acidosis in patients with impaired lactate clearance. - Significant electrolyte disturbances such as profound hypokalemia or hypernatremia.

When prescribing Glucose 5% Labesfal, clinicians should observe several precautionary measures to ensure safe use and to minimize complications.

- Monitor blood glucose levels regularly during and after infusion. - Assess fluid balance and avoid administration in patients with uncontrolled hyperglycemia. - Use caution in individuals with renal or hepatic impairment due to altered glucose metabolism. - Evaluate cardiac function before infusion in patients at risk for volume overload. - Consider pregnancy status; the safety profile in pregnant women is not well established. - Verify compatibility with other intravenous solutions before mixing.

Glucose 5% Labesfal can interact with other medications or solutions administered intravenously; awareness of these interactions helps prevent adverse events.

Avoid: - Co‑administration with other hyperosmolar glucose solutions, which may increase the risk of hyperglycemia and fluid overload. - Simultaneous infusion of high‑dose insulin without appropriate glucose monitoring. - Mixing with acidic or alkaline solutions that can cause precipitation or instability.

Use with caution: - Concurrent use of diuretics, which may exacerbate electrolyte shifts. - Administration alongside corticosteroids or catecholamines that raise blood glucose levels. - Co‑infusion with potassium supplements; monitor serum potassium closely.